What's happening now

Utrecht, 14 April 2022 – The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical

Oss, the Netherlands and Mannheim, Germany – 21 February 2022 PPSC and CeMOS have formed a strategic partnership to provide

Pivot Park Screening Centre is one of the creators of the ‘Preclinical Drug Discovery’ Radboud Summer School hosted by Pivot

Pivot Park is an incubator for ideation, innovation, and development. With its large regional and international network in biopharma, Pivot

Dr. Saman Honarnejad, Director of Drug Discovery at Pivot Park Screening Centre has been appointed as an external member of

Over the last few months, as the world has grappled with the COVID-19 pandemic, the European Lead Factory has been

One of the sub-projects of the MMV-PDP Consortium recently received funding from the Bill and Melinda Gates Foundation, to further develop an

The zebrafish (Danio rerio) is a tropical fish with a genetic structure surprisingly similar to ours. However, they’ve become a

Arginase-1 is a promising new drug target for cancer immunotherapy. A novel assay technology for High-Throughput Screening (HTS) of Arginase-1

Immunotherapy is one of the recent advances in cancer treatment. Cancer immunotherapy makes use of the body’s immune system to